---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-073870"
form_type: "8-K"
ticker: "BJDX"
cik: "0001704287"
company_name: "Bluejay Diagnostics, Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:32:55.508482+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bluejay Diagnostics Q2 update: SYMON-II enrollment starts, 510(k) target 2027

## Summary
- SYMON-II pivotal trial enrollment began; aims to validate IL-6 for 28-day mortality in ICU patients.
- Raised $3.85M in April 2025 warrant inducement financing; anticipates more capital through 2027.
- Amended Toray license extends cartridge manufacturing timeline to October 2026.
- SanyoSeiko engaged as CMO for Symphony analyzer; cartridge redevelopment via FDA-registered CMO.
- No detailed financial results disclosed; company pre-revenue with clinical and operational progress.

## SEC filing metadata
- accession: 0001213900-25-073870
- form_type: 8-K
- ticker: BJDX
- cik: 0001704287
- company_name: Bluejay Diagnostics, Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704287/000121390025073870/0001213900-25-073870-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704287/000121390025073870/ea0252557-8k_bluejay.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-073870
- JSON: https://secwatch.observer/filing/0001213900-25-073870.json
- Plain text: https://secwatch.observer/filing/0001213900-25-073870.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.